Close
CDMO Safety Testing 2026
Novotech

Moberg licenses OTC Nalox drug to Meda

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

AstraZeneca’s Baxfendy Wins FDA Approval for Uncontrolled Hypertension

AstraZeneca's hypertension drug baxdrostat, branded as Baxfendy, has received...
- Advertisement -

Moberg Derma has given marketing license for its over-the-counter Nalox to Meda as a treatment for discolored and damaged nails caused by nail fungus or nail psoriasis.

The new deal covers several major European countries, such as Germany, France, the UK, Spain, Austria, the Netherlands and Belgium.Under the deal, Meda is responsible to pay a sum of SEK 32m, with SEK13m when signing the contract and the remaining SEK19m in future milestone payments to Moberg.Moberg CEO Peter Wolpert said this agreement is a key step in the global launch of Nalox.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

AstraZeneca’s Baxfendy Wins FDA Approval for Uncontrolled Hypertension

AstraZeneca's hypertension drug baxdrostat, branded as Baxfendy, has received...

EU Advances Critical Medicines Act to Cut Import Reliance

The European Union has moved closer to implementing new...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป